EPHA2 and glioblastoma: Additionally, various CAR target antigens in GBM tumors, including B7-H3 (47, 48), HER2 (49–51), and EphA2 (52), have been demonstrated in advanced phase I clinical trials using HER2-CAR T cells and in other preclinical studies (50, 53).